FORTE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7163 USD | -3.07% |
|
-2.41% | -12.83% |
| 18/03 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 05/01 | Camac Partners Provides Information to Shareholders | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 26.07M 2.17B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 9 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.1% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -3.07% | ||
| 1 week | -2.41% | ||
| Current month | +2.89% | ||
| 1 month | +0.93% | ||
| 3 months | -4.15% | ||
| 6 months | +52.34% | ||
| Current year | -12.83% |
1 week
0.71
0.77
1 month
0.620.78
Current year
0.440.85
1 year
0.381.15
3 years
0.3843.57
5 years
0.3853.99
10 years
0.3853.99
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Wagner
CEO | Chief Executive Officer | 53 | 01/17/01 |
Anthony Riley
DFI | Director of Finance/CFO | 57 | 01/20/01 |
| Chief Operating Officer | - | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Gryska
BRD | Director/Board Member | 68 | 10/23/10 |
Steven Kornfeld
BRD | Director/Board Member | 56 | 01/20/01 |
| Director/Board Member | 65 | 12/22/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.7163 | -3.07% | 5,789 |
| 25/24/25 | 0.739 | +2.65% | 2,845 |
| 24/24/24 | 0.7199 | -2.53% | 14,300 |
| 23/24/23 | 0.7386 | +2.58% | 4,701 |
| 22/24/22 | 0.72 | -1.91% | 16,031 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Companyâs FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Companyâs subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7163
USD
Average target price
2.875
USD
Spread / Average Target
+301.37%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.83% | 26.07M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- FBRX Stock
